$LCTX announced it will report Q3 2026 financial and operating results on Thursday, November 12, 2026. Management will host a conference call at 4:30 p.m. ET/ 1:30 p.m. PT to provide a business update.
For more: https://t.co/NcwWiKq3Q3
#ReplaceAndRestore
We appreciate @AlexZank from @CFOBrew featuring $LCTX’s CFO Jill Howe, to discuss our approach to advancing promising cell therapy opportunities. Jill shares how we use our AlloSCOPE™ platform to identify therapeutic programs with strong market potential and how we strategically allocate capital to move them forward.
For the full article, see here: https://t.co/Vs63T7h7fd
#CellTherapy #Biotech #RegenerativeMedicine #CFO #LifeSciences
$LCTX’s @CEO_Culley is looking forward to joining Ben Beneski, SVP & CTO of @AllogeneTx, on the next live @_CellandGenewebinar, moderated by @Erin_Harris1 to discuss the requirements for #celltherapy late-stage development and commercialization.
Register to watch on 11/12 here: https://t.co/cA87bloF7U
#CellTherapy #GeneTherapy #RegenerativeMedicine #ReplaceandRestore
It was amazing to meet last week with the world renowned “father” of islet cell transplants @CamilloRicordi of @DRIFoundation_ & @umiamimedicine to discuss ILT1, our islet cell transplant program. His work led to $ELED and he literally invented the donor islet isolation device. An incredible career with so many new possibilities ahead. $LCTX
$LCTX today provided an update on its ReSonanceTM (ANP1) program for #hearingloss. The program is built on our patented AlloSCOPETMmanufacturing platform, and is currently being developed under a research collaboration with William Demant Invest A/S (WDI).
Learn more: https://t.co/PGjt7YM4eL
@CEO_Culley | #ReplaceAndRestore #CellTherapy #HearingLoss #RegenerativeMedicine @ca_navntoft
#CTS2026 replays are now available on demand.
$LCTX’s @CEO_Culley was proud to sit alongside presenters from @AbbVie, Oculis, @Valitorbio, @NeurotechPharma, @RecenseM and others, as part of the “From Innovation to Approval: Bringing Novel Treatments to Market” panel, moderated by Pravin U. Dugel, M.D., of @OCUTX.
Watch the recorded sessions: https://t.co/yz8vX6Rf5V
#CTSRetina #ClinicalTrials #Ophthalmology #CellTherapy #ReplaceandRestore | @CEO_Culley@ArshadKhanani@CTS_Tahoe
$LCTX wishes to thank everyone who participated in the Spinal Cord Injury Patient-Focused Drug Development Meeting, especially individuals living with #SCI and care partners who shared their experiences and perspectives.
Several themes came through clearly, including how restoring any kind of function, even incremental improvements, can translate into meaningful changes in everyday activities, personal care and quality of life.
@CEO_Culley #SCIPFDD #SCI #PFDD @reevefoundation@CIRMnews@U2FP_CureSCI@ASIA_spine@PVA1946@NASCIC1@UnitedSpinal@SCoBIRC
$LCTX congratulates @ca_navntoft and the Eriksholm Research Center for their review of the current status of cell therapy for restoring auditory nerve function, which highlights the importance of combining #celltherapy with surgical approaches to help people with hearing loss.
We look forward to continued progress on our ReSonance® (ANP1) program, an auditory neuronal cell transplant program to treat hearing loss.
Read the full article: https://t.co/OYGxqSt9ZB
#ReplaceAndRestore #HearingLoss | @CEO_Culley
Today, $LCTX announced the issuance of a U.S. Patent covering the company’s proprietary AlloSCOPE™ 5D manufacturing platform.
https://t.co/jue5dgoiQg
#CellManufacturing#ReplaceAndRestore
On #WorldSCIDay, all of us at $LCTX would like to recognize decades of collective global effort to raise awareness, strengthen prevention, and advance meaningful action for people living with spinal cord injury.
Learn more about World SCI Day:
https://t.co/jgm2e6TDaS
@CEO_Culley | @ISCoSmeetings #CellTherapy #SCI
$LCTX reported second quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update.
Learn more: https://t.co/W5BLP0YxpE
@CEO_Culley | #ReplaceAndRestore
$LCTX announced it will report Q2 2026 financial and operating results on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update.
For more: https://t.co/2DXb8raX5z
#ReplaceAndRestore
$LCTX thanks @DDWJournal for featuring @CEO_Culley in its Summer 2026 issue. Brian discusses the potential of cell replacement therapies in ophthalmology, including Lineage’s recently launched and wholly owned COR1 program, and the AlloSCOPE™ platform. https://t.co/KnwZWSk2PB
$LCTX wishes to thank @Eyecelerator and distinguished moderators @allenho and SriniVas Sadda, MD, FARVO, for including the OpRegen® cell therapy program in the panel “Is Vision Improvement on the Horizon for Regenerative Medicine?” at Eyecelerator @ ARVO 2026.
Watch the full panel: https://t.co/qArMQn9CUj
@CEO_Culley | @GenentechEye | #CellTherapy #RegenerativeMedicine #Ophthalmology #DryAMD
$LCTX will discuss progress with its COR1 preclinical program for corneal endothelial disease during a conference call today at 4:30 p.m. ET / 1:30 p.m. PT.
For more: https://t.co/IaZORcMQR6
#Ophthalmology#ReplaceandRestore